VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - March 7, 2007) - Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, announced today that the results of the completed Phase Ib clinical trial of their product AL-108 met all of its objectives. The trial confirmed that AL-108 is safe and well tolerated in 32 healthy elderly subjects after seven days of dosing.
